Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?

Literature DB >> 26831183

Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?

Sigrid V Carlsson¹, Michael W Kattan².

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 26831183 DOI： 10.1038/nrclinonc.2016.11

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

× No keyword cloud information.

13 in total

1. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.

Authors: Andrew J Stephenson; Alex Smith; Michael W Kattan; Jaya Satagopan; Victor E Reuter; Peter T Scardino; William L Gerald
Journal: Cancer Date: 2005-07-15 Impact factor: 6.860

2. Expected population impacts of discontinued prostate-specific antigen screening.

Authors: Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg
Journal: Cancer Date: 2014-07-25 Impact factor: 6.860

3. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.

Authors: Anna Grenabo Bergdahl; Ulrica Wilderäng; Gunnar Aus; Sigrid Carlsson; Jan-Erik Damber; Maria Frånlund; Kjell Geterud; Ali Khatami; Andreas Socratous; Johan Stranne; Mikael Hellström; Jonas Hugosson
Journal: Eur Urol Date: 2015-12-24 Impact factor: 20.096

4. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

Authors: Dipen J Parekh; Sanoj Punnen; Daniel D Sjoberg; Scott W Asroff; James L Bailen; James S Cochran; Raoul Concepcion; Richard D David; Kenneth B Deck; Igor Dumbadze; Michael Gambla; Michael S Grable; Ralph J Henderson; Lawrence Karsh; Evan B Krisch; Timothy D Langford; Daniel W Lin; Shawn M McGee; John J Munoz; Christopher M Pieczonka; Kimberley Rieger-Christ; Daniel R Saltzstein; John W Scott; Neal D Shore; Paul R Sieber; Todd M Waldmann; Fredrick N Wolk; Stephen M Zappala
Journal: Eur Urol Date: 2014-10-27 Impact factor: 20.096

5. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

Authors: Ahmedin Jemal; Stacey A Fedewa; Jiemin Ma; Rebecca Siegel; Chun Chieh Lin; Otis Brawley; Elizabeth M Ward
Journal: JAMA Date: 2015-11-17 Impact factor: 56.272

6. Against diagnosis.

Authors: Andrew J Vickers; Ethan Basch; Michael W Kattan
Journal: Ann Intern Med Date: 2008-08-05 Impact factor: 25.391

7. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal: Lancet Date: 2014-08-06 Impact factor: 79.321

8. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

Authors: Henrik Grönberg; Jan Adolfsson; Markus Aly; Tobias Nordström; Peter Wiklund; Yvonne Brandberg; James Thompson; Fredrik Wiklund; Johan Lindberg; Mark Clements; Lars Egevad; Martin Eklund
Journal: Lancet Oncol Date: 2015-11-10 Impact factor: 41.316

9. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

Authors: Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda
Journal: J Urol Date: 2015-01-28 Impact factor: 7.450

10. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

Authors: Richard J Bryant; Daniel D Sjoberg; Andrew J Vickers; Mary C Robinson; Rajeev Kumar; Luke Marsden; Michael Davis; Peter T Scardino; Jenny Donovan; David E Neal; Hans Lilja; Freddie C Hamdy
Journal: J Natl Cancer Inst Date: 2015-04-11 Impact factor: 13.506

8 in total

1. The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments.

Authors: Sigrid V Carlsson; Michael W Kattan
Journal: Nat Rev Clin Oncol Date: 2016-05-10 Impact factor: 66.675

Review 2. What's new in screening in 2015?

Authors: Sigrid V Carlsson; Monique J Roobol
Journal: Curr Opin Urol Date: 2016-09 Impact factor: 2.309

Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?

1. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.

2. Expected population impacts of discontinued prostate-specific antigen screening.

3. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.

4. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

5. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

6. Against diagnosis.

7. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

8. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

9. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

10. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

1. The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments.

Review 2. What's new in screening in 2015?

3. The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments.

Review 4. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.

Review 5. Prostate cancer screening-when to start and how to screen?

6. Identifying the role of apolipoprotein A-I in prostate cancer.

Review 7. The Metabolic Phenotype of Prostate Cancer.

Review 8. Advances of Zinc Signaling Studies in Prostate Cancer.